Elevated Methylation of OPRM1 and OPRL1 Genes in Alzheimer's Disease

Overview

Journal Mol Med Rep

Specialty Molecular Biology

Date 2018 Aug 29

PMID 30152845

Citations 14

Authors

Chunshuang Xu

Guili Liu

Huihui Ji

Weihua Chen

Dongjun Dai

Zhongming Chen

Dongsheng Zhou

Lei Xu

Haochang Hu

Wei Cui

Lan Chang

Qin Zha

Liping Li

Shiwei Duan

Qinwen Wang

Affiliations

Soon will be listed here.

Abstract

Previous studies have suggested that increased opioid receptor κ1 (OPRK1) and opioid receptor δ1 (OPRD1) methylation levels are involved in Alzheimer's disease (AD). In the present study, the methylation levels of two opioid receptor genes, opioid receptor µ1 (OPRM1) and opioid related nociceptin receptor 1 (OPRL1), were analyzed for their association with AD. Gene methylation levels were measured using bisulfite pyrosequencing in DNA samples derived from blood samples of 51 AD patients and 63 controls. The results indicated that there were significantly elevated promoter methylation levels of OPRM1 and OPRL1 in AD (OPRM1: P=0.007; OPRL1: P=2.987x10‑6). Dual‑luciferase reporter gene assays demonstrated that the promoter fragments of these two genes were able to promote gene expression (OPRM1: Fold‑change=2.616, P=0.003; OPRL1: Fold change=11.395, P=0.007). In addition, receiver operating characteristic analyses further indicated that a methylation panel of four opioid receptor genes (area under the curve=0.848, sensitivity=0.723, and specificity=0.879) performed well in the prediction of AD. These results suggested that opioid receptor genes may be used as potential methylation biomarkers for the diagnosis of AD.

Citing Articles

Delta-opioid receptor signaling alleviates neuropathology and cognitive impairment in the mouse model of Alzheimer's disease by regulating microglia homeostasis and inhibiting HMGB1 pathway.

Xu Y, Shao N, Zhi F, Chen R, Yang Y, Li J Alzheimers Res Ther. 2025; 17(1):35.

PMID: 39893485 PMC: 11786345. DOI: 10.1186/s13195-025-01682-1.

Pleiotropic Associations with Alzheimer's Disease and Physical Activity: Sex Differences and the Effects of Environment.

Loika Y, Loiko E, Culminskaya I, Kulminski A Int J Mol Sci. 2024; 25(23).

PMID: 39684283 PMC: 11641332. DOI: 10.3390/ijms252312571.

Complementary value of molecular, phenotypic, and functional aging biomarkers in dementia prediction.

Engvig A, Kalleberg K, Westlye L, Leonardsen E Geroscience. 2024; .

PMID: 39446224 DOI: 10.1007/s11357-024-01376-w.

Impact and Interrelationships of Striatal Proteins, EPHB2, OPRM1, and PER2 on Mild Cognitive Impairment.

Campomayor N, Kim H, Lee H, Sayson L, Ortiz D, Cho E Mol Neurobiol. 2024; 62(2):1478-1492.

PMID: 39002057 PMC: 11772528. DOI: 10.1007/s12035-024-04334-x.

A Mouse Model of Sporadic Alzheimer's Disease with Elements of Major Depression.

Bobkova N, Chuvakova L, Kovalev V, Zhdanova D, Chaplygina A, Rezvykh A Mol Neurobiol. 2024; 62(2):1337-1358.

PMID: 38980563 DOI: 10.1007/s12035-024-04346-7.

References

Snyder S, Childers S . Opiate receptors and opioid peptides. Annu Rev Neurosci. 1979; 2:35-64. DOI: 10.1146/annurev.ne.02.030179.000343. View

Gaveriaux-Ruff C, Matthes H, Peluso J, Kieffer B . Abolition of morphine-immunosuppression in mice lacking the mu-opioid receptor gene. Proc Natl Acad Sci U S A. 1998; 95(11):6326-30. PMC: 27678. DOI: 10.1073/pnas.95.11.6326. View

Armstrong R . What causes alzheimer's disease?. Folia Neuropathol. 2013; 51(3):169-88. DOI: 10.5114/fn.2013.37702. View

Jiang D, Zheng D, Wang L, Huang Y, Liu H, Xu L . Elevated PLA2G7 gene promoter methylation as a gender-specific marker of aging increases the risk of coronary heart disease in females. PLoS One. 2013; 8(3):e59752. PMC: 3610900. DOI: 10.1371/journal.pone.0059752. View

Ji H, Wang Y, Liu G, Xu X, Dai D, Chen Z . OPRK1 promoter hypermethylation increases the risk of Alzheimer's disease. Neurosci Lett. 2015; 606:24-9. DOI: 10.1016/j.neulet.2015.08.027. View

Cai Z, Ratka A . Opioid system and Alzheimer's disease. Neuromolecular Med. 2012; 14(2):91-111. DOI: 10.1007/s12017-012-8180-3. View

Doehring A, Oertel B, Sittl R, Lotsch J . Chronic opioid use is associated with increased DNA methylation correlating with increased clinical pain. Pain. 2013; 154(1):15-23. DOI: 10.1016/j.pain.2012.06.011. View

Zhang H, Wang F, Kranzler H, Zhao H, Gelernter J . Profiling of childhood adversity-associated DNA methylation changes in alcoholic patients and healthy controls. PLoS One. 2013; 8(6):e65648. PMC: 3683055. DOI: 10.1371/journal.pone.0065648. View

Peluso J, LaForge K, Matthes H, Kreek M, Kieffer B, Gaveriaux-Ruff C . Distribution of nociceptin/orphanin FQ receptor transcript in human central nervous system and immune cells. J Neuroimmunol. 1998; 81(1-2):184-92. DOI: 10.1016/s0165-5728(97)00178-1. View

10.

Piaceri I, Nacmias B, Sorbi S . Genetics of familial and sporadic Alzheimer's disease. Front Biosci (Elite Ed). 2013; 5(1):167-77. DOI: 10.2741/e605. View

11.

Ghebranious N, Mukesh B, Giampietro P, Glurich I, Mickel S, Waring S . A pilot study of gene/gene and gene/environment interactions in Alzheimer disease. Clin Med Res. 2010; 9(1):17-25. PMC: 3064752. DOI: 10.3121/cmr.2010.894. View

12.

Cunningham C, Rothman R, Prisinzano T . Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A. Pharmacol Rev. 2011; 63(2):316-47. PMC: 3082450. DOI: 10.1124/pr.110.003244. View

13.

Barg J, BELCHEVA M, Rowinski J, Ho A, BURKE W, Chung H . Opioid receptor density changes in Alzheimer amygdala and putamen. Brain Res. 1993; 632(1-2):209-15. DOI: 10.1016/0006-8993(93)91155-l. View

14.

Sun Y, Sahbaie P, Liang D, Li W, Shi X, Kingery P . DNA Methylation Modulates Nociceptive Sensitization after Incision. PLoS One. 2015; 10(11):e0142046. PMC: 4633178. DOI: 10.1371/journal.pone.0142046. View

15.

Levran O, Yuferov V, Kreek M . The genetics of the opioid system and specific drug addictions. Hum Genet. 2012; 131(6):823-42. PMC: 3721349. DOI: 10.1007/s00439-012-1172-4. View

16.

Conason A, Sher L . Alcohol use in adolescents with eating disorders. Int J Adolesc Med Health. 2006; 18(1):31-6. DOI: 10.1515/ijamh.2006.18.1.31. View

17.

Chang L, Wang Y, Ji H, Dai D, Xu X, Jiang D . Elevation of peripheral BDNF promoter methylation links to the risk of Alzheimer's disease. PLoS One. 2014; 9(11):e110773. PMC: 4217733. DOI: 10.1371/journal.pone.0110773. View

18.

Wang Y, Wang Y, Liu T, Law P, Loh H, Qiu Y . μ-Opioid receptor attenuates Aβ oligomers-induced neurotoxicity through mTOR signaling. CNS Neurosci Ther. 2014; 21(1):8-14. PMC: 6495561. DOI: 10.1111/cns.12316. View

19.

Butelman E, Kreek M . Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders. Front Pharmacol. 2015; 6:190. PMC: 4561799. DOI: 10.3389/fphar.2015.00190. View

20.

Xu X, Ji H, Liu G, Wang Q, Liu H, Shen W . A significant association between BDNF promoter methylation and the risk of drug addiction. Gene. 2016; 584(1):54-59. DOI: 10.1016/j.gene.2016.03.010. View